The first KYSCO webinar - Matthew Kurian @matthewkurianmd.bsky.social oncodaily.com/blog/255763 #Cancer #CancerResearch #CancerTreatment #KYSCO #Webinar #Medicine #Health #Oncology #OncoDaily

🔍 Does AI reduce #clinician workload? @NEJM study on @NuanceDragon DAX Copilot, an AI-powered documentation tool, found minimal impact on EHR efficiency & financial metrics❗️ 💡AI tools need to be developed in comjuction with 🩺🥼🧑‍⚕️ not in silos #AIinMedicine #LLMs @oncoalert.bsky.social

Day 2 at the San Antonio Breast Cancer Symposium was packed with insights - Jasmin Hundal @sabcs.bsky.social @jhundal.bsky.social @aryaroy.bsky.social @matthewkurianmd.bsky.social @sabcs.bsky.social oncodaily.com/insight/jasm... #Cancer #OncoDaily #Oncology #SABCS24 #Medicine #Health

Day 2 of OncLive News Network: On Location at #SABCS24 is ready for your viewing! Check out the #HER2 #bcsm updates from Drs Sara Hurvitz of @fredhutch.bsky.social & @neil-iyengarmd.bsky.social of @mskcancercenter.bsky.social hosted of course by Dr Chandler Park! www.onclive.com/view/unveili...

Fantastic event held yesterday by the @oncbrothers.bsky.social - truly thought provoking discussion with giants in the breast cancer space! Honored to be apart of it! @neil-iyengarmd.bsky.social @laurahuppert.bsky.so @drsgraff.bsky.social #sabcs2024 #signifymd

Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074]. 44 month first-line PFS! @oncbrothers.bsky.social #SABCS

Congratulations to Dr. Ali for presenting @swog.org 0221 results at @sabcs.bsky.social @oncoalert.bsky.social @clevelandclinic.bsky.social

Great real world case discussion including #OSU @stoverlab.bsky.social @osuwexmed.bsky.social on the use of liquid biopsies in #mBC treatment decisions @sabcs.bsky.social #SABCS24 #bcsm Take Away - not ready for broad use in all pts, but may help in specific cases and holds promise for future

Fantastic results from EMBER-3 showing response with abemaciclib + imlunestrant with ORR of 35% in combination for ESR1m HR+ adjuvant and ABC patients and specifically showed in those with ESR1m ⬆️PFS from 11.1m to 5.5m with combo vs oral SERD alone. #sabcs2024 @breastcancerdoc.bsky.social

EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al! www.nejm.org/doi/full/10....

Dr. Dos Santos presents data around how the breast is changed during pregnancy...and persists (not just during pregnancy)! 🤰 May explain why parity and age impacts breast cancer risk 📊. Early pregnancy ⬇️ breast cancer risk by 30-40% #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social #bcsm

Need some simplification regarding ovarian suppression in premenopausal women? Nice summary by Prudence Francis from @petermaccc.bsky.social of who are candidates for OS + AI vs tamoxifen and timing of these agents is crucial! #sabcs2024

Planning your career after fellowship? Our article on ASCO connection explores the pros & cons of academia, community & hybrid practices! A practical guide to help fellows make informed decision! @matthewkurianmd.bsky.social Rajat Thawani!

Here at #SABCS24? Let’s discuss the current SoC & how the data will change/reinforce our practice from #SABCS24! In Person, 📆: Dec11, 2024 ⏰: 7:00-9:00PM Register: bit.ly/aiosabcs24 #OncSky #AdvInOnc24 #bcsm @drsarahsammons.bsky.social @drgattimays.bsky.social @drsgraff.bsky.social

RSclin for node positive ER+ patients is validated! I hope it’s available to use soon. Always helpful to have tools to estimate recurrence and chemo benefit in these hard conversations with patients! ascopubs.org/doi/10.1200/...

Dr. Abirami Natarajan and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss adjuvant #ribociclib in this Annals of Oncology editorial. 👀 check it out here: sciencedirect.com/science/arti...

Congrats to all who’ve matched into heme/onc fellowship! Beginning of an exciting journey! If you are a future or current fellow deciding your career trajectory check out my commentary with colleagues as we discuss the differences in practice settings! connection.asco.org/do/navigatin...

An outstanding group for those who are looking for the #OncSky Cancer Care community of professionals here on BlueSky. @oncoalert.bsky.social @pallonccop.bsky.social

Thanks for posting! A favorite activity is the recordings I do with Sara Tolaney around new data at our international meetings! @oncoalert.bsky.social @ucsfcancer.bsky.social

Good to see more and more organizations in alignment with starting at 40. Key point also is that everyone should be getting a breast cancer risk assessment starting at age 25 and reassessing periodically after to see if they are high risk and need earlier screening w additional modalities.

Study in #JAMAOnc from Scotland/Wales of nearly 50k #breastcancer patients suggests vaginal estrogen use *NOT* associated w increase risk of breast cancer-specific mortality. More reassuring data 👍 jamanetwork.com/journals/jam...

Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!